Company: AZN
Filing Date: 2025-09-17
Form Type: 6-K
Source: 0001654954-25-010845
Chunk: 2

Company: ASTRAZENECA PLC
Filing Date: 2025-09-17
Form: 6-K
Chunk 2
---
 every eight weeks thereafter). 14 All participants remained on their background therapy, ICS/LABA/LAMA. 14

In the trial, moderate COPD exacerbations were defined by symptomatic worsening of COPD requiring the use of systemic corticosteroids for at least three days and use of antibiotics. 14 Severe exacerbations were defined by hospitalisation or death due to COPD. 14 Key secondary endpoints included the annualised rate of severe exacerbations, change from baseline in SGRQ total score; and change from baseline in pre-dose/pre-bronchodilator FEV1 at Week 56. 14

#### Fasenra
Fasenra (benralizumab) is currently approved as an add-on maintenance treatment for adults with SEA in more than 80 countries, including the US, Japan, EU and China. 2-5 More than 150,000 patients globally are currently taking Fasenra . 15 In the US and Japan, Fasenra is also approved in SEA patients six years and older. 6 Fasenra is also approved in more than 60 countries for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in adults. 7

The NATRON Phase III trial evaluating Fasenra (benralizumab) in people with hypereosinophilic syndrome (HES) successfully met the primary endpoint. Fasenra , dosed monthly in a single injection, demonstrated a statistically significant increase in the time to first worsening or flare compared to placebo. 16

Fasenra was developed by AstraZeneca and is in-licensed from BioWa, Inc., a wholly owned subsidiary of Kyowa Kirin Co., Ltd., Japan.

#### AstraZeneca in Respiratory & Immunology
Respiratory & Immunology, part of AstraZeneca BioPharmaceuticals, is a key disease area and growth driver to the Company.

AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases. The Company is committed to addressing the vast unmet needs of these chronic, often debilitating, diseases with a pipeline and portfolio of inhaled medicines, biologics and new modalities aimed at previously unreachable biologic targets. Our ambition is to deliver life-changing medicines that help eliminate COPD as a leading cause of death, eliminate asthma attacks and achieve clinical rem